Martínez-Galán et al. [47] reported that the hypermethylation of the promoter region of the ESR1 gene in breast cancer patients will affect the expression of the estrogen receptor protein, and concluded that epigenetic markers in plasma might be a new target for anticancer therapy, especially in endocrine therapy. This evidence concerns the gene ESR1 and breast carcinoma.